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Abstract
Objective—To identify maternal clinical risk factors for postcesarean maternal infection in a 
randomized clinical trial of preincision extended-spectrum antibiotic prophylaxis.
Methods—We conducted a planned secondary analysis of a randomized clinical trial. Patients 
were ≥ 24 weeks of gestation and delivered by cesarean delivery after a minimum of 4 hours of 
ruptured membranes or labor. All participants received standard preincision prophylaxis and were 
randomized to receive azithromycin or placebo. The primary outcome for this analysis is maternal 
infection: a composite outcome of endometritis, wound infection (superficial or deep), or other 
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infections occurring up to 6 weeks postpartum. Maternal clinical characteristics associated with 
maternal infection, after controlling for azithromycin assignment, were identified. These maternal 
factors were included in a multivariable logistic regression model for maternal infection.
Results—Of 2,013 patients, 1,019 were randomized to azithromycin. Overall, 177 (8.8%) had 
postcesarean maternal infection. In the final adjusted model, compared to the reference groups, 
women of Black race–ethnicity, with a nontransverse uterine incision, with duration of membrane 
rupture > 6 hours, and surgery duration > 49 minutes, were associated higher odds of maternal 
infection (all with adjusted odds ratios of ∼2); azithromycin was associated with lower odds of 
maternal infection (adjusted odds ratio of 0.4, 95% confidence interval 0.3-0.6.
Conclusions—Despite preincision azithromycin-based extended spectrum antibiotic 
prophylaxis, postcesarean maternal infection remains a significant source of morbidity. 
Recognition of risk factors may help guide innovative prevention strategies.
Introduction
Cesarean delivery, the most common major U.S. surgical procedure[1] is the greatest risk 
factor for puerperal maternal infection. Compared to vaginal delivery, cesarean delivery is 
associated with at least a 5 to10 fold increase in risk for postpartum (surgical site) infections 
including endometritis and wound infection.[2] As many as 60-70% of all cesarean 
deliveries are unscheduled. Even with standard preincision prophylaxis surgical site 
infection occurs in 10-15% of these deliveries. [3, 4]
A systematic review of current published data concluded that among available interventions 
to further reduce postcesarean surgical site infections, azithromycin-based extended-
spectrum prophylaxis (a single intravenous dose of azithromycin in addition to standard 
prophylaxis) might reduce the risk of postcesarean infection compared to standard 
cephalosporin alone.[5] In a randomized clinical trial of over 2000 women undergoing 
unscheduled and non-elective cesarean delivery, compared to placebo, we found that adding 
azithromycin to standard preincision prophylaxis reduced surgical site infection by 50% (12 
versus 6.1%), with a relative risk (RR) of 0.51 and 95% confidence interval (CI) of 0.38 to 
0.68; p<0.001.[6] In an effort to identify actionable prevention strategies for further clinical 
trials, the purpose of this secondary analysis was to identify maternal clinical risk factors for 
postcesarean maternal infection in the context of a trial of azithromycin-based extended 
spectrum antibiotic prophylaxis.
Materials and Methods
This is a planned secondary analysis of the Cesarean Section Optimal Antibiotic Prophylaxis 
trial (CT.gov NCT01235546), a double blind multicenter pragmatic randomized trial 
conducted at 9 clinical centers (14 sites) from 2011 to 2014. Each clinical site provided 
Institutional Review Board approval, and all participants gave written informed consent. An 
independent multidisciplinary Data Safety and Monitoring Board monitored the study 
throughout its implementation for performance and safety.
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The details for the primary clinical trial have been published.[6] Briefly, women with a 
singleton pregnancy at ≥ 24 weeks of gestation who were undergoing a non-elective 
cesarean delivery (during labor, defined as ongoing contractions with documented cervical 
change, or at least 4 hours after membrane rupture) were eligible for randomization. 
Exclusion criteria were maternal medical complications precluding macrolide use; multiple 
gestation; known azithromycin or macrolide allergy; vaginal delivery; elective or scheduled 
cesarean prior to labor or membrane rupture; use of azithromycin, erythromycin or other 
macrolide antibiotic within 7 days of randomization; chorioamnionitis or other active 
bacterial infection at the time of randomization requiring antibiotic therapy, and fetal demise 
or known major congenital anomaly. Group B streptococci positive patients receiving 
intrapartum antibiotic prophylaxis for this indication were not excluded from participation.
Patients were assigned to receive standard antibiotic prophylaxis with cefazolin, given 
according to each study site's clinical practice, which was typically prior to incision and 
weight-adjusted. Patients with cephalosporin or severe penicillin allergy received the study 
site-specific alternative (typically clindamycin alone or clindamycin + gentamycin). Patients 
were randomized to either azithromycin (500mg) or identical placebo (saline). Study drug 
was intended to be given up to one-hour prior to skin incision, and infused over at least one 
hour. Clinical providers gave routine postcesarean care at each center. Study outcomes and 
other data were abstracted and entered by trained certified study staff.
The primary outcome for this secondary analysis is maternal puerperal infection: a 
composite of endometritis, wound infection (superficial or deep), or other infections 
(abdominopelvic abscess, maternal sepsis, pelvic septic thrombophlebitis) occurring up to 6 
weeks postpartum. Endometritis was defined as the presence of two or more of the following 
signs with no other recognized cause: fever > 38° Centigrade (100.4° Fahrenheit), abdominal 
pain, uterine tenderness, or purulent drainage from uterus. Wound infection required the 
presence of either superficial or deep incisional surgical site infection characterized by 
cellulitis–erythema and induration around the incision or purulent discharge from the 
incision site with or without fever and included necrotizing fasciitis (wound hematoma, 
seroma, or breakdown alone in the absence of the preceding signs did not constitute 
infection). Abdominal or pelvic abscess required radiological or surgical confirmation of a 
purulent fluid collection.
Maternal characteristics examined included demographic, perinatal and surgical risk factors. 
These risk factors were collected accordingly: ethnicity was self-reported and then 
categorized as Hispanic, non-Hispanic Black, non-Hispanic White, or other. Body mass 
index, calculated by record maternal height and weight at delivery, was categorized 
according to the National Institute of Health/World Health Organization obesity 
classifications[7, 8]: body mass index < 25 kg/m2 is underweight or normal weight, 25-29.9 
kg/m2 as overweight and ≥ 30 kg/m2 as obese. Private pay was defined as private insurance 
versus those without or with government insurance. Additional maternal characteristics 
included maternal age at the time of screening, smoking status, primary cesarean delivery, 
group B streptococcus colonization status, diabetes status (further classified into 
pregestational and gestational diabetes), and steroid use for any reason during pregnancy. 
Additional perinatal characteristics included intrauterine pressure catheter use, induced labor 
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for any reason, and amnioinfusion. The duration of ruptured membranes was defined as the 
total number of hours between membrane rupture and infant delivery. Duration of rupture of 
membranes was further classified into 6 hours increments: ≤ 6 hours; >6-12 hours; >12-18 
hours; >18-24 hours; and > 24 hours. Surgical duration was defined as time from skin 
incision to skin closure, and further categorized as based on quartiles, which corresponded to 
≤ 38 minutes; >38-49 minutes; >49-60 minutes, and > 60 minutes.
Other surgical characteristics included skin incision (vertical or transverse), uterine incision 
(transverse versus non-transverse), and skin closure (staples and Dermabond [topical skin 
adhesive] versus sutures).
Maternal demographic, perinatal and surgical characteristics were evaluated individually 
using logistic regression modeling, controlling for randomization to azithromycin. 
Characteristics identified as statistically significant at a 0.05 level or by large effect size 
(odds ratio [OR], >1.5 or <0.7) were included as covariates in a multivariable logistic 
regression model. Interaction terms between azithromycin use and individual characteristics 
were evaluated for significance at the .05 level; if significant, the characteristic and its 
interaction term were included in the multivariable model. A parsimonious regression model 
was determined using backward selection, whereby statistically non-significant (p>0.05) 
characteristics were sequentially removed from the model. The characteristic with the largest 
p-value was eliminated in each iteration until reaching a final, reduced model where the 
remaining covariates were statistically significant at 0.05 level. SAS, version 9.2 (SAS 
Institute Inc, Cary, NC) was used for all statistical analysis.
Results
A total of 2,013 women (Table 1) were randomized to azithromycin (N=1019) or to placebo 
(N=994), of whom 177 (8.8%) were diagnosed with the composite outcome of maternal 
infection Maternal age, race–ethnicity, private pay, membrane rupture duration, surgery 
duration, intrauterine pressure catheter use, vertical skin incision, non-transverse uterine 
incision, induced labor, and staple skin closures were all significantly associated with 
maternal infection after controlling for azithromycin dosing at delivery (Table 2). Only 
staples and topical skin adhesive use had a significant interaction term, which was carried 
forward to the multivariable model.
In the final parsimonious logistic regression model (Table 2), maternal age, Black race–
ethnicity, membrane rupture duration greater than 6 hours, surgery duration greater than 49 
minutes, and non-transverse uterine incision remained as significant risk factors for maternal 
infection, even while controlling for azithromycin assignment. Azithromycin was protective 
against development of maternal infection.
Discussion
We identified maternal characteristics associated with postcesarean infection after adjusting 
for azithromycin extended-spectrum antibiotic prophylaxis. Specifically, Black race, 
duration of membrane rupture and duration of surgery were associated with increased 
maternal infection risk. Our findings demonstrate areas that should be studied in the future 
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to identify potentially modifiable risk factors remains critical for development of new 
prevention strategies for cesarean-associated puerperal infection.
Duration of membrane rupture[16, 17], increasing maternal body mass index[18-20], 
incision length and corticosteroid use[21] have been previously reported as a risk factor for 
postcesarean infection. Studies have reported inconsistent results on risk for maternal 
infection after classical compared to low-transverse uterine incisions.[22, 23] Consistent 
with prior studies, we found that the risk for postcesarean maternal infection was 1.9 to 3.4-
fold higher as ROM increased beyond 6 hours, even after adjusting for azithromycin use. In 
our analysis neither incision type nor maternal obesity were independent risk factors for 
maternal infection.
Strengths of this secondary analysis are that the primary study was a large, double-blind 
multi-center randomized control trial implemented in multiple centers. Outcomes were 
centrally adjudicated limiting internal bias. A study limitation is that women undergoing a 
scheduled cesarean and those with chorioamnionitis were excluded in the parent trial; thus 
our findings cannot be extrapolated to these groups. In addition, we were not able to assess 
effect of surgical techniques (blunt versus sharp entry), surgeon experience, or type of skin 
disinfectant–antisepsis, as these data were not collected at the individual subject level.
Our findings of risk factors for postcesarean infection must be considered in the context of 
the patients enrolled in the trial. The majority of participating study sites were tertiary care 
training centers, and almost 50% of patients reported a BMI > 30 mg/kg2. Thus, the risk 
factors for infection identified in this secondary analysis may not be generalizable to all U.S. 
women undergoing cesarean delivery. In addition, very few maternal infections occurred in 
women with a BMI < 25 mg/kg2, which creates a wide confidence interval around the odds 
ratio for infection in this group.
Additional intraoperative doses of antibiotics, at intervals one or two times the half-life of 
the drug, are recommended to maintain adequate levels throughout the length of the 
procedure. [29, 30] Thus, a second dose cefazolin is recommended for surgeries greater than 
3 hours.[29] However, these recommendations are not based on obstetric data. We found that 
the risk for maternal infection was higher despite extended spectrum prophylaxis with 
azithromycin for surgery duration greater than 49 minutes. Since the half-life of cefazolin is 
1.8 hours and the increased plasma volume in pregnancy may result in lower drug 
concentrations, it may be reasonable to investigate earlier repeat dosing.
In conclusion, although extended spectrum prophylaxis as given in the primary study 
reduced postcesarean infections, black women, and those with ruptured membranes greater 
than 6 hours, or surgery duration greater than 49 minutes remained at significantly higher 
risk for infection. Further study and consideration is needed to determine whether alternative 
timing or dosing of antibiotics for patients with these risk factors can further reduce 
postcesarean infectious morbidity.
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Table 1
Maternal characteristics of women with and without postcesarean infection*
Maternal Characteristic Maternal infection (n = 177) No maternal infection (n = 1836) P value
Azithromycin (n=1019) 60 (33.9%) 959 (52.2%) <0.001
Years of Age, mean ± SD 26.6 ± 6.3 28.4 ± 6.3 0.001
Hispanic and Other 53 (29.9%) 570 (31.1%) 0.001
Black 81 (45.8%) 611 (33.3%)
White 43 (24.3%) 655 (35.7%)
Body mass index ≥ 30 kg/m2 145 (81.9%) 1328 (73.3%) 0.020
Body mass index 25-30 kg/m2 28 (15.8%) 410 (22.4%)
Body mass index < 25 kg/m2 4 (2.3%) 94 (5.1%)
Private Pay 36 (20.7%) 593 (32.6%) 0.001
Pre-gestational diabetes 11 (6.2%) 72 (3.9%) 0.22
Gestational diabetes 14 (7.9%) 191 (10.4%)
No diabetes 152 (85.9%) 1573 (85.7%)
Smoker 22 (12.4%) 197 (10.7%) 0.49
Group B streptococci positive 36 (20.3%) 479 (26.1%) 0.09
Preterm < 37 weeks 19 (10.7%) 207 (11.3%) 0.83
Primary cesarean 144 (81.4%) 1379 (75.1%) 0.06
Intrauterine pressure catheter use 140 (79.1%) 1144 (62.3%) <0.001
Non-transverse uterine incision 11 (6.3%) 70 (3.8%) 0.10
Vertical skin incision 13 (7.3%) 64 (3.5%) 0.011
Induced labor 116 (65.5%) 978 (53.4%) 0.002
Steroids for any reason 16 (9.0%) 145 (7.9%) 0.59
 Steroids for lung maturity 12 (6.8%) 94 (5.1%) 0.35
 Steroids for all other reasons 4 (2.3%) 56 (3.1%) 0.55
Amnioinfusion 29 (16.4%) 288 (15.7%) 0.81
Duration of membrane rupture
 ≤ 6 hours 33 (18.6%) 608 (33.3%) 0.003
 > 6 - 12 hours 60 (33.9%) 593 (32.5%)
 > 12 - 18 hours 43 (24.3%) 355 (19.5%)
 > 18 -24 hours 28 (15.8%) 164 (9.0%)
 > 24 hours 13 (7.3%) 105 (5.8%)
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Maternal Characteristic Maternal infection (n = 177) No maternal infection (n = 1836) P value
Surgery Duration
 ≤ 38 minutes 35 (19.9%) 520 (28.4%) 0.031
 39 - 49 minutes 39 (22.2%) 449 (24.5%)
 > 49 - 60 minutes 50 (28.4%) 419 (22.9%)
 > 60 minutes 52 (29.6%) 445 (24.3%)
Skin Closure
 Staples 79 (44.6%) 749 (40.8%) 0.32
 Sutures/topical skin adhesive 98 (55.4%) 1087 (59.2%)
*data presented as number (column %) except age
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Table 2
Unadjusted and adjusted odds ratios (OR), 95% confidence intervals (CI) of maternal 
clinical factors for postcesarean maternal infection, n=2013
Maternal Characteristic Unadjusted OR (95% CI) Adjusted OR* (95% CI)
Azithromycin assignment 0.5 (0.3-0.6) 0.4 (0.3-0.6)
Age, (years, mean ± SD) 0.95 (0.93-0.98) 0.95 (0.93-0.98)
Hispanic and Other 1.4 (0.9-2.1) 1.4 (0.9-2.2)
Black 2.0 (1.4-3.0) 1.9 (1.3-2.8)
White Ref Ref
Body Mass Index ≥ 30 kg/m2 2.5 (0.9-6.9)
Body Mass Index 25-30 kg/m2 1.5 (0.5-4.5)
Body Mass Index < 25 kg/m2 Ref -
Private Pay 0.5 (0.4-0.8) -
Pregestational diabetes 1.6 (0.8-3.1)
Gestational diabetes 0.7 (0.4-1.3)
No diabetes Ref -
Smoker 1.1 (0.7-1.8) -
Group B Streptococci colonization 0.7 (0.5-1.0) -
Preterm delivery < 37 weeks 0.94 (0.57-1.6) -
Primary cesarean 1.5 (0.97-2.1) -
Intrauterine pressure catheter use 2.3 (1.6-3.3) -
Nontransverse uterine incision 1.8 (0.9-3.4) 2.0 (1.03-4.0)
Vertical skin incision 2.1 (1.1-3.9) -
Induced labor 1.6 (1.2-2.3) -
Steroids for any reason 1.1 (0.7-2.0) -
 Steroids for lung maturity 1.4 (0.7-2.6) -
 Steroids for all other reasons 0.7 (0.2-1.9) -
Amnioinfusion 1.0 (0.7-1.6) -
Duration of membrane rupture
 ≤ 6 hours Ref Ref
 > 6 - 12 hours 1.9 (1.2-3.0) 1.9 (1.2-3.1)
 > 12 - 18 hours 2.3 (1.4-3.7) 2.5 (1.5-4.1)
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Maternal Characteristic Unadjusted OR (95% CI) Adjusted OR* (95% CI)
 > 18 -24 hours 3.3 (2.0-5.7) 3.7 (2.1-6.4)
 > 24 hours 2.4 (1.2-4.8) 2.7 (1.4-5.5)
Surgery Duration
 ≤ 38 minutes Ref Ref
 39 - 49 minutes 1.3 (0.8-2.2) 1.5 (0.9-2.5)
 > 49 - 60 minutes 1.9 (1.2-2.9) 2.0 (1.3-3.2)
 > 60 minutes 1.8 (1.2-2.9) 2.1 (1.3-3.4)
Skin Closure (significant interaction with treatment)
 For azithromycin group:
  Staples/topical skin adhesive 0.44 (0.3-0.8) -
  Sutures Ref
 For placebo group: 1.48 (1.01-2.2)
  Staples/topical skin adhesive Ref -
  Sutures
*Adjusted for age, race/ethnicity, membrane rupture and surgery duration, non-transverse uterine incision, and assignment to azithromycin
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